Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.
复制标题
DOI：
10.1097/pap.0000000000000161
复制
发表时间：
2017-11
影响因子：
6.7
通讯作者：
Fox SB
中科院分区：
文献类型：
--
作者：
Hendry S;Salgado R;Gevaert T;Russell PA;John T;Thapa B;Christie M;van de Vijver K;Estrada MV;Gonzalez-Ericsson PI;Sanders M;Solomon B;Solinas C;Van den Eynden GGGM;Allory Y;Preusser M;Hainfellner J;Pruneri G;Vingiani A;Demaria S;Symmans F;Nuciforo P;Comerma L;Thompson EA;Lakhani S;Kim SR;Schnitt S;Colpaert C;Sotiriou C;Scherer SJ;Ignatiadis M;Badve S;Pierce RH;Viale G;Sirtaine N;Penault-Llorca F;Sugie T;Fineberg S;Paik S;Srinivasan A;Richardson A;Wang Y;Chmielik E;Brock J;Johnson DB;Balko J;Wienert S;Bossuyt V;Michiels S;Ternes N;Burchardi N;Luen SJ;Savas P;Klauschen F;Watson PH;Nelson BH;Criscitiello C;O'Toole S;Larsimont D;de Wind R;Curigliano G;André F;Lacroix-Triki M;van de Vijver M;Rojo F;Floris G;Bedri S;Sparano J;Rimm D;Nielsen T;Kos Z;Hewitt S;Singh B;Farshid G;Loibl S;Allison KH;Tung N;Adams S;Willard-Gallo K;Horlings HM;Gandhi L;Moreira A;Hirsch F;Dieci MV;Urbanowicz M;Brcic I;Korski K;Gaire F;Koeppen H;Lo A;Giltnane J;Rebelatto MC;Steele KE;Zha J;Emancipator K;Juco JW;Denkert C;Reis-Filho J;Loi S;Fox SB
随着肿瘤免疫反应的预后意义日益被认识到，以及免疫疗法在不同肿瘤类型中被评估和实施，对肿瘤免疫反应的评估变得越来越重要。然而，许多不同的方法可用于评估和描述免疫反应，这限制了作为常规临床生物标志物实施的努力。在本综述的第一部分中，我们基于浸润性乳腺癌的国际免疫肿瘤学生物标志物工作组指南，提出了一种评估实体肿瘤中肿瘤浸润淋巴细胞（til）的标准化方法。在本综述的第二部分，我们讨论了TILs在常见实体肿瘤中的预后和预测价值的现有证据，包括肺癌、胃肠道、泌尿生殖系统、妇科系统、头颈部，以及原发性脑肿瘤、间皮瘤和黑色素瘤。讨论了不同肿瘤类型TIL评价的特殊性和不同侧重点。我们提出的标准化方法可以适应不同的肿瘤类型，并可作为其他方法可以比较的标准。TIL评估的标准化将有助于临床医生、研究人员和病理学家最终评估这一简单生物标志物在当前免疫治疗时代的实用性。
Assessment of the immune response to tumors is growing in importance as the prognostic implications of this response are increasingly recognized, and as immunotherapies are evaluated and implemented in different tumor types. However, many different approaches can be used to assess and describe the immune response, which limits efforts at implementation as a routine clinical biomarker. In part 1 of this review, we have proposed a standardized methodology to assess tumor infiltrating lymphocytes (TILs) in solid tumors, based on the International Immuno-Oncology Biomarkers Working Group guidelines for invasive breast carcinoma. In part 2 of this review, we discuss the available evidence for the prognostic and predictive value of TILs in common solid tumors, including carcinomas of the lung, gastrointestinal tract, genitourinary system, gynecological system, and head and neck, as well as primary brain tumors, mesothelioma and melanoma. The particularities and different emphases in TIL assessment in different tumor types are discussed. The standardized methodology we propose can be adapted to different tumor types and may be used as a standard against which other approaches can be compared. Standardization of TIL assessment will help clinicians, researchers and pathologists to conclusively evaluate the utility of this simple biomarker in the current era of immunotherapy.